Pursuant to Regulation 32(6) of the Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the Monitoring Agency Report dated November 13, 2026 in respect of the utilization of proceeds raised through the Initial Public Offering of the Company.

VALPLAST TECHNOLOGIES LIMITED www.valplastech.com VALPLAST November 14, 2026 Head of the Department, Department of Listing Operation, BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai — 400001 Scrip Code — 544565 Scrip ID: VALPLAST Dear Sir/Madam, Sub: Submission of Monitoring Agency Report for the quarter ended September 30, 2026. Pursuant to Regulation 32(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed the Monitoring Agency Report dated November 13, 2026, issued by CARE Ratings Limited, the Monitoring Agency, for the quarter ended September 30, 2026, in respect of the utilization of proceeds raised through the Initial Public Offering of the Company. The aforesaid Monitoring Agency Report was placed before and considered by the Audit Committee of the Company at its meeting held on 14.11.2026 and was thereafter taken on record for submission to the Stock Exchange. Kindly take the above disclosure and the enclosed report on record. Thanking you, Yours faithfully For Valplast Technologies Limited Shivangi Dixit Company Secretary and Compliance Officer Membership No. A71527 Place: Noida Date: 14.11.2026 Encl.: Monitoring Agency Report for the quarter ended September 30, 2026. We Do Challenging Jobs Registered Office : Corporate Office : Unit BH-1025, 10™ Floor, Unit No. 1109 11 Floor, TowerA, - Puri Business Hub, 81 High Street, Advant IT Park, Plot No. 7, ARG Seectcotr or 8811,, FariFadriadabbaad,d , H Haryana -121004 Seectcotr or 142, E xpressway NoNiodiad a - 121004 w001 £ &P « :0-1 292770900 « :0-1 482899000 MTFECERT, HReTie 3 : info@valplastindia.com = : info@valplastindia.com CorticationSody CIN : LA5400HR2014PLC094931 Care=dge RATINGS CARE/NRO/GEN/2026-27/1183 The Board of Directors Valplast Technologies Limited 109, Tower A, Advant IT Park, Sector 142 Noida, Uttar Pradesh, 201304 November 13, 2026 Dear Sir/Ma’am, Monitoring Agency Report for the quarter ended September 30,2026 - in relation to the IPO of Valplast Technologies Limited (“the Company”) We write in our capacity of Monitoring Agency for the IPO for the amount aggregating to Rs. 28.09 crore of the Company and refer to our duties cast under regulation 262 of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations. In this connection, we are enclosing the Monitoring Agency Report for the quarter ended September 30,2026 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated September 08,2025. Request you to kindly take the same on records. Thanking you, Yours faithfully, Dhruv Mittal Assistant Director Dhruv.mittal@careedge.in oth floor, C-001/A2, Berger Towers, Sector 168, 4th Floor, Godirej Coliseum, Somaiya Hospital Road,- Noida, Off Eastern Express Highway, Sion (East), Mumbai - Gautam Budh Nagar, Uttar Pradesh -201301 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: care@careedge.in * www.careedge.in Care=dge RATINGS Report of the Monitoring Agency Name of the issuer: Valplast Technologies Limited For quarter ended: September 30,2026 Name of the Monitoring Agency: CARE Ratings Limited (a) Deviation from the objects: No deviation (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Phowy Signature: - Name and designation of the Authorized Signatory: Dhruv Mittal Designation of Authorized person/Signing Authority: Assistant Director oth floor, C-001/A2, Berger Towers, Sector 168, 4th Floor, Godirej Coliseum, Somaiya Hospital Road,- Noida, Off Eastern Express Highway, Sion (East), Mumbai - Gautam Budh Nagar, Uttar Pradesh -201301 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: care@careedge.in * www.careedge.in Care=dge RATINGS 1) Issuer Details: Name of the issuer : Valplast Technologies Ltd Name of the promoter : Mr. Sanjay Kumar and Mr. Rajeev Tyagi Industry/sector to which it belongs : Construction 2) Issue Details Issue Period : September 30,2025 and closed on October 03,2025 Type of issue (public/rights) . IPO Type of specified securities : Equity Shares IPO Grading, if any : Not available Issue size (in crore) :Rs. 28.09 crore 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information / certifications Comments of the Comments of the Particulars Reply considered by Monitoring Agency for Board of Monitoring Agency preparation of report Directors Whethearll utilization is as per the disclosures in the Offer Bank statements, Offer documents, CA All utilization during Q2FY27 is as per Yes . . No comments Document? certificate*, Management certificate objects of offer. A special resolution passed through postal ballot on June 28, 2026 where members of the company have approved the reallocation of the portion of unutilized funds previously Whether shareholder approval has been obtained in case of CA certificate*, Management allocated towards “Capital material deviations# from expenditures disclosed in the Offer Yes certificate, Special resolution and No comments expenditure” to the objects “General Document? Board resolution corporate purpose” and “Working capital requirements”. Further, board resolution dated September 24, 2026 clarified and confirmed that while the aforesaid 9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godirej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai - Noida, Gautam Budh Nagar, Uttar Pradesh -201301 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: care@careedgein + www.careedge.in Care=dge RATINGS Source of information / certifications Comments of the Comments of the Particulars Reply considered by Monitoring Agency for Board of Monitoring Agency preparation of report Directors resolution provides for utilization of the issue proceeds towards General corporate purpose (GCP) and Working capital, the said purposes are provided as the approv [Showing first 8,000 characters — download PDF for full document]